Future Chemoradiation Strategies in Pancreatic Cancer

Seminars in Oncology

Volumn 34, Issue 4, 2007, Pages 335-346

  Crane, Christopher H ^a   Varadhachary, Gauri ^a   Pisters, Peter W T ^a   Evans, Douglas B ^a   Wolff, Robert A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; ERLOTINIB; FLUOROURACIL; GEFITINIB; GEMCITABINE; OXALIPLATIN; PACLITAXEL;

ADVANCED CANCER; ARTICLE; BLOOD TOXICITY; CANCER LOCALIZATION; CANCER STAGING; CANCER SURGERY; CLINICAL STUDY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DEHYDRATION; DIARRHEA; DRUG DOSE ESCALATION; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LOW DRUG DOSE; NAUSEA AND VOMITING; PANCREAS CANCER; PANCREAS SURGERY; PATIENT SELECTION; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; STEREOTAXIC SURGERY;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FLUOROURACIL; FORECASTING; HUMANS; NEOADJUVANT THERAPY; PANCREATIC NEOPLASMS; PATIENT SELECTION; RADIOTHERAPY, ADJUVANT;

EID: 34547435279     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2007.05.001     Document Type: Article

References (69)

1. In: Greene F.L., Page D.L., Fleming I.D., et al. (Eds). AJCC Cancer Staging Manual. (ed 6) (2002), Springer, New York, NY 157-164
2. Tseng J.F., Raut C.P., Lee J.E., Pisters P.W., et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg 8 (2004) 935-949
3. Macdonald J.S., Smalley S.R., Benedetti J., et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345 (2001) 725-730
4. Krook J.E., Moertel C.G., Gunderson L.L., et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 324 (1991) 709-715
5. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 59 (1987) 2006-2010
6. Kapiteijn E., Marijnen C.A., Nagtegaal I.D., et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345 (2001) 638-646
7. Breslin T.M., Hess K.R., Harbison D.B., et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: Treatment variables and survival duration. Ann Surg Oncol 8 (2001) 123-132
8. Sohn T.A., Yeo C.J., Cameron J.L., et al. Resected adenocarcinoma of the pancreas-616 patients: Results, outcomes, and prognostic indicators. J Gastrointest Surg 4 (2000) 567-579
9. Lim J.E., Chien M.W., and Earle C.C. Prognostic factors following curative resection for pancreatic adenocarcinoma: A population-based, linked database analysis of 396 patients. Ann Surg 237 (2003) 74-85
10. Klinkenbijl J.H., Jeekel J., Sahmoud T., et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann Surg 230 (1999) 776-782
11. Neoptolemos J.P., Stocken D.D., Friess H., et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350 (2004) 1200-1210
12. Sauer R., Becker H., Hohenberger W., et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351 (2004) 1731-1740
13. Raut C.P., Evans D.B., Crane C.H., et al. Neoadjuvant therapy for resectable pancreatic cancer. Surg Oncol Clin North Am 4 (2004) 639-661
14. Pisters P.W.T., Wolff R.A., Janjan N.A., et al. Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: Toxicities, histologic response rates, and event-free outcome. J Clin Oncol 20 (2002) 2537-2544
15. Pisters P.W., Abbruzzese J.L., Janjan N.A., et al. Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J Clin Oncol 16 (1998) 3843-3850
16. Lowy A.M., Lee J.E., Pisters P.W., et al. Prospective, randomized trial of octreotide to prevent pancreatic fistula after pancreaticoduodenectomy for malignant disease. Ann Surg 226 (1997) 632-641
17. Sohn T.A., Yeo C.J., Cameron J.L., et al. Resected adenocarcinoma of the pancreas-616 patients: Results, outcomes, and prognostic indicators. J Gastrointestinal Surg 4 (2000) 567-579
18. Pisters P.W., Wolff R.A., Crane C.H., et al. Combined-modality treatment for operable pancreatic adenocarcinoma. Oncology 19 (2005) 393-404
19. Pisters P.W.T., Abbruzzese J.L., Janjan N.A., et al. Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J Clin Oncol 16 (1998) 3843-3850
20. Evans D.B., Rich T.A., Byrd D.R., et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 127 (1992) 1335-1339
21. Wolff R.A., Evans D.B., Crane C.H., et al. Initial results of a preoperative gemcitabine (GEM)-based chemoradiation for resectable pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 21 (2002) 130a (abstr)
22. Wolff R.A., Evans D.B., Gravel D.M., et al. Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res 7 (2001) 2246-2253
23. Rich T.A., Janjan N.A., Abbruzzese J.L., et al. (Response) Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 15 (1997) 3292-3293
24. Pisters P.W.T., Hudec W.A., Hess K.R., et al. Effect of preoperative biliary decompression on pancreaticoduodenectomy-associated morbidity in 300 consecutive patients. Ann Surg 234 (2001) 47-55
25. Pisters P.W.T., Hudec W.A., Lee J.E., et al. Preoperative chemoradiation for patients with pancreatic cancer: Toxicity of endobiliary stents. J Clin Oncol 18 (2000) 860-867
26. Suits J., Frazee R., and Erickson R.A. Endoscopic ultrasound and fine needle aspiration for the evaluation of pancreatic masses. Arch Surg 134 (1999) 639-643
27. Faigel D., Ginsberg G., Bentz J., et al. Endoscopic ultrasound-guided real-time fine-needle aspiration biopsy of the pancreas in cancer patients with pancreatic lesions. J Clin Oncol 15 (1997) 1439-1443
28. Hoffman J.P., Lipsitz S., Pisansky T., et al. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: An Eastern Cooperative Oncology Group study. J Clin Oncol 16 (1998) 317-323
29. Povoski S.P., Karpeh M.S., Conlon K.C., et al. Association of preoperative biliary drainage with postoperative outcome following pancreaticoduodenectomy. Ann Surg 230 (1999) 131-142
30. The Gastrointestinal Tumor Study Group. A multi-institutional comparative trial of radiation therapy alone and in combination with 5-fluorouracil for locally unresectable pancreatic carcinoma. Ann Surg 189 (1979) 205-208
31. Moertel C.G., Frytak S., Hahn R.G., et al. Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 48 (1981) 1705-1710
32. Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 80 (1988) 751-755
33. Gastrointestinal Tumor Study Group. Radiation therapy combined with Adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma. Cancer 56 (1985) 2563-2568
34. Klaassen D.J., MacIntyre J.M., Catton G.E., et al. Treatment of locally unresectable cancer of the stomach and pancreas: A randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil-An Eastern Cooperative Oncology Group study. J Clin Oncol 3 (1985) 373-378
35. Whittington R., Neuberg D., Tester W.J., et al. Protracted intravenous fluorouracil infusion with radiation therapy in the management of localized pancreaticobiliary carcinoma: A phase I Eastern Cooperative Oncology Group trial. J Clin Oncol 13 (1995) 227-232
36. Ishii H., Okada S., Tokuuye K., et al. Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma. Cancer 79 (1997) 1516-1520
37. Pipas J.M., Mitchell S.E., Barth R.J., et al. Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 50 (2001) 1317-1322
38. McGinn C.J., Zalupski M.M., Shureiqi I., et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 19 (2001) 4202-4208
39. Blackstock A.W., Bernard S.A., Richards F., et al. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol 17 (1999) 2208-2212
40. Crane C.H., Wolff R.A., Abbruzzese J.L., et al. Combining gemcitabine with radiation in pancreatic cancer: Understanding important variables influencing the therapeutic index. Semin Oncol 28 (2001) 25-33
41. Li C.-P., Chao Y., Chi K.-H., et al. Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: Gemcitabine versus 5-fluorouracil, a randomized controlled study. Int J Radiat Oncol Biol Physics 57 (2003) 98-104
42. Blackstock A., Tempero M., Niedwiecki D., et al. Cancer and Leukemia Group B (CALGB) 89805: Phase II chemoradiation trial using gemcitabine in patients with localoregional adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Physics 51 (2001) 31 (abstr 49)
43. McGinn C.J., Zalupski M.M., Shureiqi I., et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 19 (2001) 4202-4208
44. McGinn C, Talamonti M, Small W, et al: A phase II trial of full-dose gemcitabine with concurrent radiation therapy in patients with resectable or unresectable non-metastatic pancreatic cancer. Proceedings of the 2004 ASCO Gastrointestinal Symposium, San Francisco, CA, January 16-18, 2004, p 89 (abstr 96)
45. Burris III H.A., Moore M.J., Andersen J., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15 (1997) 2403-2413
46. Crane C.H., Abbruzzese J.L., Evans D.B., et al. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?. Int J Radiat Oncol Biol Physics 52 (2002) 1293-1302
47. Twelves C., Weng A., Nowacki M.P., et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352 (2005) 2696-2704
48. Cartwright T.H., Cohn A., Varkey J.A., et al. Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 20 (2002) 160-164
49. Dunst J., Reese T., Sutter T., et al. Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J Clin Oncol 20 (2002) 3983-3991
50. Crane C., Ellis L., Abbruzzese J., et al. Phase I trial of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic adenocarcinoma. J Clin Oncol 24 (2006) 1145-1151
51. Ben-Josef E., Shields A.F., Vaishampayan U., et al. Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer. Int J Radiat Oncol Biol Physics 59 (2004) 454-459
52. Saif M.W., Eloubeidi M.A., Russo S., et al. Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: Expression analysis of genes related to outcome. J Clin Oncol 23 (2005) 8679-8687
53. Gorski D.H., Beckett M.A., Jaskowiak N.T., et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59 (1999) 3374-3378
54. Wey J., Fan F., Gray M., et al. Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines. Cancer 104 (2005) 427-438
55. Jain R.K. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307 (2005) 58-62
56. Willett C.G., Boucher Y., di Tomaso E., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10 (2004) 145-147
57. Iannitti D.M.D., Dipetrillo T.M.D., Akerman P.M.D., et al. Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: A phase I study. Am J Clin Oncol 28 (2005) 570-575
58. Czito B.G., Willett C.G., Bendell J.C., et al. Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: Phase I trial results. J Clin Oncol 24 (2006) 656-662
59. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (2006) 567-578
60. Tamm E.P., Silverman P.M., Charnsangavej C., et al. Diagnosis, staging, and surveillance of pancreatic cancer. AJR 180 (2003) 1311-1323
61. Cusack J.C., Fuhrman G.M., Lee J.E., et al. Management of unsuspected tumor invasion of the superior mesenteric-portal venous confluence at the time of pancreaticoduodenectomy. Am J Surg 168 (1994) 352-354
62. Jessup J.M., Steele Jr. G., Mayer R.J., et al. Neoadjuvant therapy for unresectable pancreatic adenocarcinoma. Arch Surg 128 (1993) 559-564
63. Jeekel J., and Treurniet-Donker A.D. Treatment perspectives in locally advanced unresectable pancreatic cancer. Br J Surg 78 (1991) 1332-1334
64. White R., Lee C., Anscher M., et al. Preoperative chemoradiation for patients with locally advanced adenocarcinoma of the pancreas. Ann Surg Oncol 6 (1999) 38-45
65. Todd K.E., Gloor B., Lane J.S., et al. Resection of locally advanced pancreatic cancer after downstaging with continuous-infusion 5-fluorouracil, mitomycin-C, leucovorin, and dipyridamole. J Gastrointest Surg 2 (1998) 159-166
66. Bajetta E., Di Bartolomeo M., Stani S.C., et al. Chemoradiotherapy as preoperative treatment in locally advanced unresectable pancreatic cancer patients: Results of a feasibility study. Int J Radiat Oncol Biol Physics 45 (1999) 285-289
67. Kornek G.V., Schratter-Sehn A., Marczell A., et al. Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil, leucovorin and cisplatin. Br J Cancer 82 (2000) 98-103
68. Mehta V.K., Fisher G., Ford J.A., et al. Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas. J Gastrointest Surg 5 (2001) 27-35
69. Koong A.C., Le Q.T., Ho A., et al. Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Physics 58 (2004) 1017-1021